Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

The supply of GLP-1 drugs like Ozempic has been increasing, but they’re still expensive for most patients. Here are answers ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Erin Davis/Axios Visuals More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health ...